Two new therapies, targeting molecules within the influential Interferon Type 1 (IFN-1) signaling cascade, have been shown to benefit some patients that do not respond well to standard therapies.

After years of limited therapeutic options for lupus, the development of personalized treatments offers hope to patients struggling to control their disease.